Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor.

White LE, Villa MT, Petronic-Rosic V, Jiang J, Medenica MM.

Skinmed. 2006 Mar-Apr;5(2):96-8.

PMID:
16603845
3.

Disseminated sporotrichosis mimicking sarcoidosis.

Yang DJ, Krishnan RS, Guillen DR, Schmiege LM 3rd, Leis PF, Hsu S.

Int J Dermatol. 2006 Apr;45(4):450-3.

PMID:
16650176
4.
5.

Bullous pyoderma gangrenosum in a patient with myelodysplastic syndrome during granulocyte colony-stimulating factor therapy.

Lewerin C, Mobacken H, Nilsson-Ehle H, Swolin B.

Leuk Lymphoma. 1997 Aug;26(5-6):629-32.

PMID:
9389372
6.

Unusual cutaneous manifestations of myelodysplastic syndrome.

Suzuki Y, Kuroda K, Kojima T, Fujita M, Iseki T, Shinkai H.

Br J Dermatol. 1995 Sep;133(3):483-6.

PMID:
8547011
7.

Atypical hemorrhagic bullous pyoderma gangrenosum.

Altunay IK, Sezgin SA, Ileri U, Ekmekçi TR, Kuran I, Köşlü A, Baş L.

Int J Dermatol. 2001 May;40(5):327-9.

PMID:
11554994
8.

Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma.

Miall FM, Harman K, Kennedy B, Dyer MJ.

Br J Haematol. 2006 Jan;132(1):115-6. No abstract available.

PMID:
16371028
9.

Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides.

Johnson ML, Grimwood RE.

Arch Dermatol. 1994 Jan;130(1):77-81. Review.

PMID:
7506900
11.

Florid histiocytic hemophagocytosis following therapy with long acting G-CSF (pegfilgrastim).

Glasser L, Legolvan M, Horwitz HM.

Am J Hematol. 2007 Aug;82(8):753-7.

12.

Bilateral peripheral ulcerative keratitis associated with pyoderma gangrenosum.

Bouchard CS, Meyer MA, McDonnell JF.

Cornea. 1997 Jul;16(4):480-2.

PMID:
9220248
13.

Granulocytic growth factors and cancer-related neutropenia: limited effects.

[No authors listed]

Prescrire Int. 2006 Oct;15(85):189-91.

PMID:
17128529
14.

Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.

Hashino S, Morioka M, Irie T, Shiroshita N, Kawamura T, Suzuki S, Iwasaki H, Umehara S, Kakinoki Y, Kurosawa M, Kahata K, Izumiyama K, Kobayashi H, Onozawa M, Takahata M, Fujisawa F, Kondo T, Asaka M.

Int J Lab Hematol. 2008 Aug;30(4):292-9. doi: 10.1111/j.1751-553X.2007.00955.x.

PMID:
18665826
15.

Treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis.

Kanekura T, Kawahara K, Maruyama I, Kanzaki T.

Ther Apher Dial. 2005 Aug;9(4):292-6.

PMID:
16076369
16.

Cutaneous reaction to pegfilgrastim presenting as severe generalized skin eruption.

Scott WR, Silberstein L, Flatley R, Ardeshna KM, Korostoff N, Dawe S.

Br J Dermatol. 2009 Sep;161(3):717-9. doi: 10.1111/j.1365-2133.2009.09371.x. Epub 2009 Jul 15. No abstract available.

PMID:
19614649
17.

A case report of cyclic neutropenia associated with pyoderma gangrenosum.

Jabbari H, Payvarmehr F, SeyedAlinaghi S, Roosta N.

Acta Med Iran. 2011;49(11):763-5.

18.

Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.

Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M.

Eur J Cancer. 2006 Nov;42(17):2976-81. Epub 2006 Sep 27.

PMID:
17008093
19.

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.

Lyman G, Lalla A, Barron R, Dubois RW.

Curr Med Res Opin. 2009 Feb;25(2):401-11. doi: 10.1185/03007990802636817 .

PMID:
19192985
20.

Acne fulminans coexisting with pyoderma gangrenosum-like eruptions and posterior scleritis.

Kurokawa S, Tokura Y, Nham NX, Sudoh H, Wakita H, Furukawa F, Takigawa M.

J Dermatol. 1996 Jan;23(1):37-41.

PMID:
8720256

Supplemental Content

Support Center